Alteration of clinical outcome and histopathology of yellow fever virus infection in a hamster model by previous infection with heterologous flaviviruses
- PMID: 12887029
Alteration of clinical outcome and histopathology of yellow fever virus infection in a hamster model by previous infection with heterologous flaviviruses
Abstract
Using a recently described hamster model of severe yellow fever (YF), we examined the hypothesis that prior infection with heterologous flaviviruses protects against severe or fatal YF. Hamsters were singly or sequentially infected with Japanese encephalitis, St. Louis encephalitis, West Nile, and/or dengue-1 viruses, and then challenged with a virulent strain of yellow fever virus (YFV). In contrast to control (naive) hamsters, many of which appeared clinically ill or died after YFV infection, the flavivirus-immune animals remained asymptomatic. The flavivirus-immune hamsters also had a reduced viremia and lower serum levels of alanine aminotransferase and total bilirubin, compared with naive hamsters, following YFV infection. Histologically, livers of animals in the flavivirus-immune and control groups showed comparable levels of multifocal necrapoptosis. However, steatosis was not observed in the flavivirus-immune animals, whereas naive hamsters developed extensive microvesicular steatosis in the liver following YFV infection. These findings suggest that hepatocytic steatosis is an adverse microscopic feature associated with severe disease in YFV infection. Our experimental results support earlier anecdotal reports that prior exposure of humans to heterologous flaviviruses reduces subsequent risk of fatal YFV infection.
Similar articles
-
Experimental yellow fever virus infection in the Golden Hamster (Mesocricetus auratus). I. Virologic, biochemical, and immunologic studies.J Infect Dis. 2001 May 15;183(10):1431-6. doi: 10.1086/320199. Epub 2001 Apr 17. J Infect Dis. 2001. PMID: 11319679
-
Phenotypic and molecular characterization of a non-lethal, hamster-viscerotropic strain of yellow fever virus.Virus Res. 2005 Jun;110(1-2):65-71. doi: 10.1016/j.virusres.2005.01.004. Virus Res. 2005. PMID: 15845256
-
Yellow fever 17-D vaccine is neurotropic and produces encephalitis in immunosuppressed hamsters.Am J Trop Med Hyg. 2007 Nov;77(5):919-24. Am J Trop Med Hyg. 2007. PMID: 17984354
-
Mouse and hamster models for the study of therapy against flavivirus infections.Novartis Found Symp. 2006;277:218-29; discussion 229-32, 251-3. Novartis Found Symp. 2006. PMID: 17319165 Review.
-
Treatment of yellow fever.Antiviral Res. 2008 Apr;78(1):116-24. doi: 10.1016/j.antiviral.2007.10.009. Epub 2007 Nov 20. Antiviral Res. 2008. PMID: 18061688 Review.
Cited by
-
Yellow fever virus infectivity for Bolivian Aedes aegypti mosquitoes.Emerg Infect Dis. 2004 Sep;10(9):1657-60. doi: 10.3201/eid1009.031124. Emerg Infect Dis. 2004. PMID: 15498171 Free PMC article.
-
Is there a risk of yellow fever virus transmission in South Asian countries with hyperendemic dengue?Biomed Res Int. 2013;2013:905043. doi: 10.1155/2013/905043. Epub 2013 Dec 3. Biomed Res Int. 2013. PMID: 24367789 Free PMC article. Review.
-
Anamnestic immune response to dengue and decreased severity of yellow Fever.J Glob Infect Dis. 2009 Jul;1(2):111-6. doi: 10.4103/0974-777X.56257. J Glob Infect Dis. 2009. PMID: 20300401 Free PMC article.
-
The Absence of Yellow Fever in Asia: History, Hypotheses, Vector Dispersal, Possibility of YF in Asia, and Other Enigmas.Viruses. 2020 Nov 25;12(12):1349. doi: 10.3390/v12121349. Viruses. 2020. PMID: 33255615 Free PMC article. Review.
-
Flavivirus serocomplex cross-reactive immunity is protective by activating heterologous memory CD4 T cells.Sci Adv. 2018 Jul 4;4(7):eaar4297. doi: 10.1126/sciadv.aar4297. eCollection 2018 Jul. Sci Adv. 2018. PMID: 29978039 Free PMC article.